Advertisement
Screener

Definium Therapeutics, Inc. (DFTX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

2.2 / 5 stars · 23/52 Roast Me

Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-26

  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-12-31 was $2.40M.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-09-30 was $1.60M.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-06-30 was $1.90M.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $3.80M.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $2.70M, a 64.00% decline from fiscal 2024.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $7.50M, a 2.74% increase from fiscal 2023.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $7.30M, a 24.74% decline from fiscal 2022.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $9.70M, a 59.92% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month
2025-12-31$2.70M
10-K · filed 2026-02-26
2024-12-31$7.50M
10-K · filed 2025-03-06
2023-12-31$7.30M
10-K · filed 2024-02-28
2022-12-31$2.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
$4.00M
derived: sum of 2 quarters · filed 2023-03-09
$5.90M
derived: sum of 3 quarters · filed 2023-03-09
$9.70M
10-K · filed 2023-03-09
2022-09-30$1.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$3.50M
derived: sum of 2 quarters · filed 2022-11-10
$7.30M
10-Q · filed 2022-11-10
2022-06-30$1.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$5.70M
10-Q · filed 2022-08-11
2022-03-31$3.80M
10-Q · filed 2022-05-16
2021-12-31$24.20M
10-K · filed 2022-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cronos Group Inc. (CRON)$1.223B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B